China approves Roche’s Alecensa for NSCLC

Roche (SIX:ROG; OTCQX:RHHBY) said China’s State Drug Administration approved Alecensa alectinib as monotherapy to treat anaplastic lymphoma

Read the full 173 word article

User Sign In